Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Olodaterol

Olodaterol

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Olodaterol

28 trials tracked of Olodaterol: 23 in phase 3 or 4 and 1 with published results. The most-cited published study has 24 citations.

28Trials tracked
23Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 4 Phase 3 19 Phase 2 2 Phase 1 1 Other / NA 2
  1. Phase 3 Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients Completed · 24 cited
  2. Phase 4 Cardiovascular Function in COPD Patients Completed
  3. Phase 4 Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients Completed
  4. Phase 4 The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus Completed
  5. Phase 4 Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD Completed
  6. Phase 3 Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) Completed
Show 22 more trials
  1. Phase 3 Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. Completed
  2. Phase 3 Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® Completed
  3. Phase 3 Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Completed
  4. Phase 3 Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2) Completed
  5. Phase 3 Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Completed
  6. Phase 3 Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II Completed
  7. Phase 3 Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease Completed
  8. Phase 3 12 / 48 Week Pivotal PFT vs PBO in COPD I Completed
  9. Phase 3 12 / 48 wk Pivotal PFT vs PBO in COPD II Completed
  10. Phase 3 Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. Completed
  11. Phase 3 Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I Completed
  12. Phase 3 Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II Completed
  13. Phase 3 Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® Completed
  14. Phase 3 Japan Long-term Safety for Tiotropium Plus Olodaterol Completed
  15. Phase 3 Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I Completed
  16. Phase 3 Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients Completed
  17. Phase 3 Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients Completed
  18. Phase 2 Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma Completed
  19. Phase 2 Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers Completed
  20. Phase 1 Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients Completed
  21. N/A Drug Utilization Study for Olodaterol Completed
  22. N/A Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.